Quick Answer
Dermata Therapeutics, Inc. reported Stockholders Equity of $6.22 million for the year ending 2025.
- Dermata Therapeutics, Inc. showed an increase of +298.7% in Stockholders Equity from 2024 to 2025.
- This data is from Dermata Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$1.63 million | Q2 2020: -$2.20 million | Q3 2020: -$2.78 million | Q1 2021: $712.0 thousand | Q2 2021: -$505.8 thousand | Q3 2021: $12.49 million | Q1 2022: $7.85 million | Q2 2022: $9.66 million | Q3 2022: $7.47 million | Q1 2023: $8.09 million | Q2 2023: $8.03 million | Q3 2023: $6.41 million | Q1 2024: $3.81 million | Q2 2024: $3.32 million | Q3 2024: $4.74 million | Q1 2025: $7.30 million | Q2 2025: $5.61 million | Q3 2025: $3.96 million.
- Over the full 7 years of available data (2019 to 2025), Dermata Therapeutics, Inc.'s Stockholders Equity has grown by 3,061.3%.
- Historical annual values: Fiscal year 2025: $6.22 million | Fiscal year 2024: $1.56 million | Fiscal year 2023: $6.36 million | Fiscal year 2022: $6.02 million | Fiscal year 2021: $10.11 million | Fiscal year 2020: -$3.18 million | Fiscal year 2019: -$210.2 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: